{"entity":{"type":"insider","cik":"0001571469","url":"/insider/0001571469","json_url":"/insider/0001571469.json","name":"Countouriotis Athena","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":19,"n_filings":7,"first":"2019-04-24","last":"2022-02-11","span_basis":"filed_date"},"name_variants":[{"name":"Countouriotis Athena","source":"filing","n_filings":7,"first_seen":"2019-04-24","last_seen":"2022-02-11"}],"transactions":[{"id":6423767,"accession":"0001209191-22-008979","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-22-008979","line_url":"/filing/0001209191-22-008979#line-2","is_derivative":false,"issuer_cik":"0001571469","issuer_name":"Turning Point Therapeutics, Inc.","issuer_ticker":"TPTX","issuer_name_source":null,"issuer_url":"/issuer/0001571469","owner_cik":"0001571469","owner_name":"Countouriotis Athena","owner_display_name":"Countouriotis Athena","owner_url":"/insider/0001571469","role":"Director, Officer (President & CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President & CEO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2971.0,"shares_display":"2,971","price_per_share":36.3,"price_display":"36.30","price_state":"stated","total_value":107847.3,"total_display":"107,847.30","total_whole":"107,847","shares_owned_after":47930.0,"shares_owned_after_display":"47,930","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-02-09","filed_date":"2022-02-11","scope":"insider"},{"id":5285892,"accession":"0001209191-21-009931","txn_seq":17,"anchor":"line-17","filing_url":"/filing/0001209191-21-009931","line_url":"/filing/0001209191-21-009931","is_derivative":false,"issuer_cik":"0001571469","issuer_name":"Turning Point Therapeutics, Inc.","issuer_ticker":"TPTX","issuer_name_source":null,"issuer_url":"/issuer/0001571469","owner_cik":"0001571469","owner_name":"Countouriotis Athena","owner_display_name":"Countouriotis Athena","owner_url":"/insider/0001571469","role":"Director, Officer (President & CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President & CEO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":8942.0,"shares_display":"8,942","price_per_share":137.37933460076044,"price_display":"137.38","price_state":"stated","total_value":1228446.01,"total_display":"1,228,446.01","total_whole":"1,228,446","shares_owned_after":54818.0,"shares_owned_after_display":"54,818","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-02-11","filed_date":"2021-02-11","scope":"insider","n_lines":3},{"id":5285877,"accession":"0001209191-21-009931","txn_seq":13,"anchor":"line-13","filing_url":"/filing/0001209191-21-009931","line_url":"/filing/0001209191-21-009931","is_derivative":false,"issuer_cik":"0001571469","issuer_name":"Turning Point Therapeutics, Inc.","issuer_ticker":"TPTX","issuer_name_source":null,"issuer_url":"/issuer/0001571469","owner_cik":"0001571469","owner_name":"Countouriotis Athena","owner_display_name":"Countouriotis Athena","owner_url":"/insider/0001571469","role":"Director, Officer (President & CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President & CEO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":25392.0,"shares_display":"25,392","price_per_share":136.30735625393825,"price_display":"136.31","price_state":"stated","total_value":3461116.39,"total_display":"3,461,116.39","total_whole":"3,461,116","shares_owned_after":52709.0,"shares_owned_after_display":"52,709","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-02-10","filed_date":"2021-02-11","scope":"insider","n_lines":5},{"id":5285863,"accession":"0001209191-21-009931","txn_seq":7,"anchor":"line-7","filing_url":"/filing/0001209191-21-009931","line_url":"/filing/0001209191-21-009931","is_derivative":false,"issuer_cik":"0001571469","issuer_name":"Turning Point Therapeutics, Inc.","issuer_ticker":"TPTX","issuer_name_source":null,"issuer_url":"/issuer/0001571469","owner_cik":"0001571469","owner_name":"Countouriotis Athena","owner_display_name":"Countouriotis Athena","owner_url":"/insider/0001571469","role":"Director, Officer (President & CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President & CEO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":25666.0,"shares_display":"25,666","price_per_share":138.68445959635315,"price_display":"138.68","price_state":"stated","total_value":3559475.34,"total_display":"3,559,475.34","total_whole":"3,559,475","shares_owned_after":51299.0,"shares_owned_after_display":"51,299","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-02-09","filed_date":"2021-02-11","scope":"insider","n_lines":5},{"id":2337659,"accession":"0001209191-20-032143","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-20-032143","line_url":"/filing/0001209191-20-032143#line-1","is_derivative":false,"issuer_cik":"0001571469","issuer_name":"Turning Point Therapeutics, Inc.","issuer_ticker":"TPTX","issuer_name_source":null,"issuer_url":"/issuer/0001571469","owner_cik":"0001571469","owner_name":"Countouriotis Athena","owner_display_name":"Countouriotis Athena","owner_url":"/insider/0001571469","role":"Director, Officer (President & CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President & CEO","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":4166.0,"shares_display":"4,166","price_per_share":60.0,"price_display":"60.00","price_state":"stated","total_value":249960.0,"total_display":"249,960.00","total_whole":"249,960","shares_owned_after":26872.0,"shares_owned_after_display":"26,872","ownership_form":"D","is_10b5_1":null,"transaction_date":"2020-05-21","filed_date":"2020-05-26","scope":"insider"},{"id":2781466,"accession":"0001209191-20-021188","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-20-021188","line_url":"/filing/0001209191-20-021188#line-1","is_derivative":false,"issuer_cik":"0001571469","issuer_name":"Passage BIO, Inc.","issuer_ticker":"PASG","issuer_name_source":null,"issuer_url":"/issuer/0001571469","owner_cik":"0001571469","owner_name":"Countouriotis Athena","owner_display_name":"Countouriotis Athena","owner_url":"/insider/0001571469","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":10000.0,"shares_display":"10,000","price_per_share":14.975,"price_display":"14.98","price_state":"stated","total_value":149750.0,"total_display":"149,750.00","total_whole":"149,750","shares_owned_after":18900.0,"shares_owned_after_display":"18,900","ownership_form":"D","is_10b5_1":null,"transaction_date":"2020-03-24","filed_date":"2020-03-25","scope":"insider"},{"id":3276874,"accession":"0001209191-20-015619","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-20-015619","line_url":"/filing/0001209191-20-015619#line-1","is_derivative":false,"issuer_cik":"0001571469","issuer_name":"Passage BIO, Inc.","issuer_ticker":"PASG","issuer_name_source":null,"issuer_url":"/issuer/0001571469","owner_cik":"0001571469","owner_name":"Countouriotis Athena","owner_display_name":"Countouriotis Athena","owner_url":"/insider/0001571469","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":8900.0,"shares_display":"8,900","price_per_share":18.0,"price_display":"18.00","price_state":"stated","total_value":160200.0,"total_display":"160,200.00","total_whole":"160,200","shares_owned_after":8900.0,"shares_owned_after_display":"8,900","ownership_form":"D","is_10b5_1":null,"transaction_date":"2020-03-03","filed_date":"2020-03-03","scope":"insider"},{"id":8120809,"accession":"0001209191-19-049146","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-19-049146","line_url":"/filing/0001209191-19-049146#line-1","is_derivative":false,"issuer_cik":"0001571469","issuer_name":"Turning Point Therapeutics, Inc.","issuer_ticker":"TPTX","issuer_name_source":null,"issuer_url":"/issuer/0001571469","owner_cik":"0001571469","owner_name":"Countouriotis Athena","owner_display_name":"Countouriotis Athena","owner_url":"/insider/0001571469","role":"Director, Officer (President & CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President & CEO","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":10000.0,"shares_display":"10,000","price_per_share":45.0,"price_display":"45.00","price_state":"stated","total_value":450000.0,"total_display":"450,000.00","total_whole":"450,000","shares_owned_after":22000.0,"shares_owned_after_display":"22,000","ownership_form":"D","is_10b5_1":null,"transaction_date":"2019-09-10","filed_date":"2019-09-11","scope":"insider"},{"id":8558210,"accession":"0001209191-19-025786","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-19-025786","line_url":"/filing/0001209191-19-025786#line-1","is_derivative":false,"issuer_cik":"0001571469","issuer_name":"Turning Point Therapeutics, Inc.","issuer_ticker":"TPTX","issuer_name_source":null,"issuer_url":"/issuer/0001571469","owner_cik":"0001571469","owner_name":"Countouriotis Athena","owner_display_name":"Countouriotis Athena","owner_url":"/insider/0001571469","role":"Director, Officer (President & CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President & CEO","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":12000.0,"shares_display":"12,000","price_per_share":18.0,"price_display":"18.00","price_state":"stated","total_value":216000.0,"total_display":"216,000.00","total_whole":"216,000","shares_owned_after":12000.0,"shares_owned_after_display":"12,000","ownership_form":"D","is_10b5_1":null,"transaction_date":"2019-04-22","filed_date":"2019-04-24","scope":"insider"}],"collapsed":true,"next_cursor":null,"ledger_fault":false,"count":{"value":19,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":5,"open_market":true},{"code":"S","label":"Open-market sale","n":14,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":19},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0001595893","name":"Turning Point Therapeutics, Inc.","url":"/issuer/0001595893","role":"Director, Officer (President & CEO)","n_filings":5,"first_seen":"2019-04-24","last_seen":"2022-02-11"},{"type":"issuer","type_label":"ISSUER","cik":"0001787297","name":"Passage BIO, Inc.","url":"/issuer/0001787297","role":"Director","n_filings":2,"first_seen":"2020-03-03","last_seen":"2020-03-25"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001571469","retrieved_at":"2026-08-24T12:37:24+00:00","coverage":{"filings":1506293,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-21","last_ingest":"2026-08-22T05:23:40.159918+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}